Free Trial
NASDAQ:OLMA

Olema Pharmaceuticals Q2 2024 Earnings Report

Olema Pharmaceuticals logo
$5.00 -0.01 (-0.20%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Olema Pharmaceuticals EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.54
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Olema Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Olema Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Olema Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Olema Pharmaceuticals Earnings Headlines

AI Bloodbath Coming on June 1st?
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
Q2 EPS Estimate for Olema Pharmaceuticals Raised by Analyst
See More Olema Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email.

About Olema Pharmaceuticals

Olema Pharmaceuticals (NASDAQ:OLMA), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

View Olema Pharmaceuticals Profile

More Earnings Resources from MarketBeat